Cargando…
Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
Since angiotensin increases the expression of plasminogen activator inhibitor (PAI), mechanisms associated with an actively functioning renin–angiotensin–aldosterone system can be expected to be associated with increased PAI-1 expression. These mechanisms are present not only in common conditions re...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036907/ https://www.ncbi.nlm.nih.gov/pubmed/27679717 http://dx.doi.org/10.1093/ckj/sfw080 |
_version_ | 1782455647205326848 |
---|---|
author | D'Elia, John A. Bayliss, George Gleason, Ray E. Weinrauch, Larry A. |
author_facet | D'Elia, John A. Bayliss, George Gleason, Ray E. Weinrauch, Larry A. |
author_sort | D'Elia, John A. |
collection | PubMed |
description | Since angiotensin increases the expression of plasminogen activator inhibitor (PAI), mechanisms associated with an actively functioning renin–angiotensin–aldosterone system can be expected to be associated with increased PAI-1 expression. These mechanisms are present not only in common conditions resulting in glomerulosclerosis associated with aging, diabetes or genetic mutations, but also in autoimmune disease (like scleroderma and lupus), radiation injury, cyclosporine toxicity, allograft nephropathy and ureteral obstruction. While the renin–angiotensin–aldosterone system and growth factors, such as transforming growth factor-beta (TGF-β), are almost always part of the process, there are rare experimental observations of PAI-1 expression without their interaction. Here we review the literature on PAI-1 and its role in vascular, fibrotic and oxidative injury as well as work suggesting potential areas of intervention in the pathogenesis of multiple disorders. |
format | Online Article Text |
id | pubmed-5036907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50369072016-09-27 Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review D'Elia, John A. Bayliss, George Gleason, Ray E. Weinrauch, Larry A. Clin Kidney J Cardiovascular Disease and CKD Since angiotensin increases the expression of plasminogen activator inhibitor (PAI), mechanisms associated with an actively functioning renin–angiotensin–aldosterone system can be expected to be associated with increased PAI-1 expression. These mechanisms are present not only in common conditions resulting in glomerulosclerosis associated with aging, diabetes or genetic mutations, but also in autoimmune disease (like scleroderma and lupus), radiation injury, cyclosporine toxicity, allograft nephropathy and ureteral obstruction. While the renin–angiotensin–aldosterone system and growth factors, such as transforming growth factor-beta (TGF-β), are almost always part of the process, there are rare experimental observations of PAI-1 expression without their interaction. Here we review the literature on PAI-1 and its role in vascular, fibrotic and oxidative injury as well as work suggesting potential areas of intervention in the pathogenesis of multiple disorders. Oxford University Press 2016-10 2016-08-31 /pmc/articles/PMC5036907/ /pubmed/27679717 http://dx.doi.org/10.1093/ckj/sfw080 Text en © The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Cardiovascular Disease and CKD D'Elia, John A. Bayliss, George Gleason, Ray E. Weinrauch, Larry A. Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
title | Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
title_full | Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
title_fullStr | Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
title_full_unstemmed | Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
title_short | Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
title_sort | cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review |
topic | Cardiovascular Disease and CKD |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036907/ https://www.ncbi.nlm.nih.gov/pubmed/27679717 http://dx.doi.org/10.1093/ckj/sfw080 |
work_keys_str_mv | AT deliajohna cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview AT baylissgeorge cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview AT gleasonraye cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview AT weinrauchlarrya cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview |